216 related articles for article (PubMed ID: 7909337)
21. Oxidation of dopamine and related catechols in dopaminergic brain regions in Parkinson's disease and during ageing in non-Parkinsonian subjects.
Fornstedt Wallin B
J Neural Transm (Vienna); 2024 Mar; 131(3):213-228. PubMed ID: 38238531
[TBL] [Abstract][Full Text] [Related]
22. The enigma of neuromelanin in Parkinson's disease substantia nigra.
Youdim MB; Ben-Shachar D; Riederer P
J Neural Transm Suppl; 1994; 43():113-22. PubMed ID: 7884393
[TBL] [Abstract][Full Text] [Related]
23. Iron accelerates the conversion of dopamine-oxidized intermediates into melanin and provides protection in SH-SY5Y cells.
Izumi Y; Sawada H; Yamamoto N; Kume T; Katsuki H; Shimohama S; Akaike A
J Neurosci Res; 2005 Oct; 82(1):126-37. PubMed ID: 16108071
[TBL] [Abstract][Full Text] [Related]
24. Melanin and Neuromelanin: Linking Skin Pigmentation and Parkinson's Disease.
Krainc T; Monje MHG; Kinsinger M; Bustos BI; Lubbe SJ
Mov Disord; 2023 Feb; 38(2):185-195. PubMed ID: 36350228
[TBL] [Abstract][Full Text] [Related]
25. Inducible alterations of glutathione levels in adult dopaminergic midbrain neurons result in nigrostriatal degeneration.
Chinta SJ; Kumar MJ; Hsu M; Rajagopalan S; Kaur D; Rane A; Nicholls DG; Choi J; Andersen JK
J Neurosci; 2007 Dec; 27(51):13997-4006. PubMed ID: 18094238
[TBL] [Abstract][Full Text] [Related]
26. Selectivity of melaninized nigra-striatal dopamine neurons to degeneration in Parkinson's disease may depend on iron-melanin interaction.
Ben-Shachar D; Youdim MB
J Neural Transm Suppl; 1990; 29():251-8. PubMed ID: 2193109
[TBL] [Abstract][Full Text] [Related]
27. In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PET.
Hansen AK; Knudsen K; Lillethorup TP; Landau AM; Parbo P; Fedorova T; Audrain H; Bender D; Østergaard K; Brooks DJ; Borghammer P
Brain; 2016 Jul; 139(Pt 7):2039-49. PubMed ID: 27190023
[TBL] [Abstract][Full Text] [Related]
28. Is the vulnerability of neurons in the substantia nigra of patients with Parkinson's disease related to their neuromelanin content?
Kastner A; Hirsch EC; Lejeune O; Javoy-Agid F; Rascol O; Agid Y
J Neurochem; 1992 Sep; 59(3):1080-9. PubMed ID: 1494900
[TBL] [Abstract][Full Text] [Related]
29. p-Quinone mediates 6-hydroxydopamine-induced dopaminergic neuronal death and ferrous iron accelerates the conversion of p-quinone into melanin extracellularly.
Izumi Y; Sawada H; Sakka N; Yamamoto N; Kume T; Katsuki H; Shimohama S; Akaike A
J Neurosci Res; 2005 Mar; 79(6):849-60. PubMed ID: 15712215
[TBL] [Abstract][Full Text] [Related]
30. Thiol Oxidation by Diamide Leads to Dopaminergic Degeneration and Parkinsonism Phenotype in Mice: A Model for Parkinson's Disease.
Ray A; Kambali M; Ravindranath V
Antioxid Redox Signal; 2016 Aug; 25(5):252-67. PubMed ID: 27121974
[TBL] [Abstract][Full Text] [Related]
31. Iron-melanin complex in substantia nigra of parkinsonian brains: an x-ray microanalysis.
Jellinger K; Kienzl E; Rumpelmair G; Riederer P; Stachelberger H; Ben-Shachar D; Youdim MB
J Neurochem; 1992 Sep; 59(3):1168-71. PubMed ID: 1494904
[TBL] [Abstract][Full Text] [Related]
32. 5-S-cysteinyl-dopamine, a neurotoxic endogenous metabolite of dopamine: Implications for Parkinson's disease.
Badillo-Ramírez I; Saniger JM; Rivas-Arancibia S
Neurochem Int; 2019 Oct; 129():104514. PubMed ID: 31369776
[TBL] [Abstract][Full Text] [Related]
33. Iron, melanin and dopamine interaction: relevance to Parkinson's disease.
Ben-Shachar D; Youdim MB
Prog Neuropsychopharmacol Biol Psychiatry; 1993 Jan; 17(1):139-50. PubMed ID: 8416600
[TBL] [Abstract][Full Text] [Related]
34. Oxidative metabolites of 5-S-cysteinylnorepinephrine are irreversible inhibitors of mitochondrial complex I and the alpha-ketoglutarate dehydrogenase and pyruvate dehydrogenase complexes: possible implications for neurodegenerative brain disorders.
Xin W; Shen XM; Li H; Dryhurst G
Chem Res Toxicol; 2000 Aug; 13(8):749-60. PubMed ID: 10956063
[TBL] [Abstract][Full Text] [Related]
35. Potential new insights into the molecular mechanisms of methamphetamine-induced neurodegeneration.
Wrona MZ; Yang Z; Zhang F; Dryhurst G
NIDA Res Monogr; 1997; 173():146-74. PubMed ID: 9260188
[TBL] [Abstract][Full Text] [Related]
36. Cysteinyldopamine is not incorporated into neuromelanin.
Wakamatsu K; Ito S; Nagatsu T
Neurosci Lett; 1991 Sep; 131(1):57-60. PubMed ID: 1791980
[TBL] [Abstract][Full Text] [Related]
37. Oxidative stress: a role in the pathogenesis of Parkinson's disease.
Götz ME; Freyberger A; Riederer P
J Neural Transm Suppl; 1990; 29():241-9. PubMed ID: 2193108
[TBL] [Abstract][Full Text] [Related]
38. The role of iron in senescence of dopaminergic neurons in Parkinson's disease.
Youdim MB; Riederer P
J Neural Transm Suppl; 1993; 40():57-67. PubMed ID: 8294901
[TBL] [Abstract][Full Text] [Related]
39. The roles of neuromelanin, binding of metal ions, and oxidative cytotoxicity in the pathogenesis of Parkinson's disease: a hypothesis.
Enochs WS; Sarna T; Zecca L; Riley PA; Swartz HM
J Neural Transm Park Dis Dement Sect; 1994; 7(2):83-100. PubMed ID: 7710667
[TBL] [Abstract][Full Text] [Related]
40. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease.
Hirsch E; Graybiel AM; Agid YA
Nature; 1988 Jul; 334(6180):345-8. PubMed ID: 2899295
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
